OncBioMune Invites Shareholders To Join Live Webcast Today At BIO CEO & Investors Conference

BATON ROUGE, LA--(Marketwired - February 09, 2016) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to invite shareholders and interested parties to listen live to the Company's presentation at the 2016 BIO CEO & Investor Conference at the Waldorf Astoria in New York, NY. Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will be presenting today at 3:30 PM ET in the Duke of Windsor room during the conference's Oncology Track. The presentation is being made available live at: http://www.veracast.com/webcasts/bio/ceoinvestor2016/73231196757.cfm.

An archive of the presentation will be available one hour after the conclusion of the live event at the above link. An archive of the presentation will also be available on the "Investors" section of the OncBioMune website (www.OncBioMune.com).

The presentation will include a corporate overview that includes the latest data from the ongoing Phase 1 clinical trial of ProscaVax for prostate cancer; information on the Phase 2 trial of ProscaVax planned for the first half of 2016; and other clinical and business developments.

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Back to news